Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201310-14 Development of Novel Anti-Cancer Drug for Relapsed Multiple Myeloma(Oncology, Chemical) [02.03.2014]


Development and Market Objectives

To receive fast-track FDA approval for CWP291, a potent β-catenin inhibitor that has shown excellent antitumor activity in multiple myeloma models, as a therapeutic agent and conduct multinational clinical trial research in patients suffering from relapsed and refractory multiple myeloma in Korea and the US.

Future commercialization through licensing and developmental collaboration with a multinational pharmaceutical company 

Unmet Medical Need & Target Patients

Target patients: Relapsed or refractory multiple myeloma patients who have failed 2 or more standard therapies.
Unmet Medical Needs
① Poor prognosis for many multiple myeloma patients, with high rates of relapse after receiving standard of care.
② Targeted therapies with lowered toxicity are needed, particularly because the majority of multiple myeloma patients are seniors.
③ Novel approaches that can synergize with standard therapies are needed to increase the therapeutic options available to physicians.


Preclinical studies have revealed that CWP291 demonstrates outstanding in vitro, and in vivo anti-tumor effects through the inhibition of β-catenin, a major factor implicated in relapsed and refractory multiple myeloma cases.  

In order to increase translational relevance, we are preparing for phase 1 clinical research by conducting an additional preclinical evaluation of CWP291 using a mesenchymal stem cell co-culture system, and a patient-derived (PD) model that incorporates both human myeloma cells and standard treatment resistant cells.

Intellectual Property

A material PCT patent application and US application are scheduled, with the current patent for non-clinical studies in major markets valid until 2030.

Competitive Advantages

u  First-in-class drug with potent β-catenin inhibitory effects at an early development stage in comparison to competing candidates

Exhibits outstanding in vitro/in vivo anti-cancer effects in resistant multiple myeloma models and demonstrates synergism in co-administration with standard therapy

Lower toxicity profile when compared to standard therapy and existing cytotoxic drugs

Indications may be expanded to various solid tumor types that display drug tolerance due to β-catenin overexpression 

Strong patent position and guaranteed monopoly period


Multiple Myeloma

Research Period

Jan.02, 2014 ~ Jul.31, 2014


JW Pharmaceutical Corporation

Developmental Stage


Additional Information

Contact Information

Address Company Name: JW Pharmaceutical Corporation
WebSite Homepage: Contact Person: Tae Kyoung Kim
E-mail: Contact: 82-2-840-6163

Related Projects

Related Project